Vaxcyte, Inc. $PCVX Shares Acquired by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 42.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,068,898 shares of the company’s stock after purchasing an additional 913,761 shares during the quarter. Westfield Capital Management Co. LP owned 2.36% of Vaxcyte worth $99,770,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Persistent Asset Partners Ltd grew its holdings in Vaxcyte by 116.5% during the second quarter. Persistent Asset Partners Ltd now owns 45,499 shares of the company’s stock worth $1,479,000 after acquiring an additional 24,479 shares during the period. Cetera Investment Advisers boosted its position in shares of Vaxcyte by 13.8% during the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock worth $250,000 after purchasing an additional 932 shares in the last quarter. Creative Planning grew its stake in shares of Vaxcyte by 101.3% during the 2nd quarter. Creative Planning now owns 78,470 shares of the company’s stock worth $2,551,000 after purchasing an additional 39,491 shares during the period. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Vaxcyte by 4.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 28,032 shares of the company’s stock valued at $911,000 after purchasing an additional 1,248 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Vaxcyte by 5.0% during the second quarter. Geode Capital Management LLC now owns 3,011,140 shares of the company’s stock worth $97,903,000 after buying an additional 142,086 shares in the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PCVX has been the subject of a number of research reports. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research report on Friday, September 12th. They set a “neutral” rating and a $38.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday, October 14th. Cowen reissued a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. Leerink Partners set a $77.00 price target on Vaxcyte and gave the stock an “outperform” rating in a research note on Wednesday. Finally, BTIG Research reiterated a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.83.

Vaxcyte Price Performance

Shares of PCVX stock opened at $49.10 on Thursday. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $94.76. The firm has a fifty day moving average of $40.47 and a two-hundred day moving average of $35.72. The firm has a market cap of $6.43 billion, a P/E ratio of -10.15 and a beta of 1.07.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period in the previous year, the company earned ($0.83) EPS. On average, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.